AMOEBA (EPA:ALMIB) - AMOEBA: Changes in the composition of Board of Directors

Transparency directive : regulatory news

20/06/2019 17:45

PRESS RELEASE

           Changes in the composition of AMOÉBA's Board of Directors:

* Appointment of Mrs Claudine VERMOT-DESROCHES and Mrs Ghislaine PINOCHET as
  new independent directors following the General Meeting held today

* Co-option of ELAIA PARTNERS by the Board of Directors, as director

Chassieu, June 20, 2019 - AMOÉBA (FR0011051598 - AMEBA), producer of a
biological biocide capable of eliminating bacterial risk in water and human
wounds, and a biocontrol product for plant protection, announces the
appointment of Claudine Vermot-Desroches and Ghislaine Pinochet as new Board
members.

The General Assembly, which was held today, approved the appointment of two new
directors:

* Mrs Claudine Vermot-Desroches, provisionally appointed by the Board of
  Directors on May 17, 2019, to replace Gaëtane Suzenet, for the remainder of
  her term of office, i.e. until the Ordinary General Meeting called to approve
  the financial statements for the year ending December 31, 2022.
* Mrs Ghislaine Pinochet, for a term of six years, i.e. until the General
  Meeting called to approve the financial statements for the year ending 31
  December 2024.

After examining the situation of Mrs Claudine Vermot-Desroches and Mrs
Ghislaine Pinochet with regard to the independence criteria defined by the
MiddleNext Code to which AMOÉBA refers, the Board of Directors has qualified
Mrs Vermot-Desroches and Mrs Pinochet as independent directors.

"With the appointment of Claudine Vermot-Desroches and Ghislaine Pinochet,
Amoéba is strengthening its Board of Directors to support its development and
meet future diversification challenges in new applications, particularly in the
areas of plant and human wound protection. I would like to thank Gaëtane
Suzenet for her contribution to the Board of Directors over the past few years
and welcome the arrival of our two new directors who will bring us their
respective expertise in biotechnology and plant protection." said Fabrice
PLASSON, President and CEO of AMOÉBA.

Cooptation of ELAIA PARTNERS into the Board of Directors

In addition, the Board of Directors, which met after today's General Meeting,
provisionally appointed ELAIA PARTNERS as director, represented by Mr Franck
LESCURE, to replace AURIGA PARTNERS, for the remainder of the term of office as
representative of the Bioseeds Fund, i.e. until the Ordinary General Meeting
called to approve the accounts for the financial year ending 31 December 2022,
subject to ratification by the next Ordinary General Meeting.

After more than fifteen years of venture capital in Life Sciences, Franck
Lescure joined Elaia as a Partner a year ago to form a life sciences team. He
manages investments and sits on the boards of directors of several companies in
the portfolio of the PSL Innovation Fund and, as part of a management
delegation granted by Auriga Partners of Elaia, the Bioseeds fund. Sacha
Loiseau and Frédéric Hammel strengthen the Life Sciences team as Venture
Partners.

AMOÉBA's Board of Directors is composed of seven members, including three
women and four independent directors.

Claudine Vermot Desroches

Claudine has a PhD in molecular biology and immunology from the University of
Lyon and a post-doctoral fellowship from the University of Helsinki. She has
more than 25 years' experience in the field of biotherapies and masters the
value chain of a biomedicine covering the identification of a medical need,
target validation, the generation and evaluation of biological drugs, the
development of industrial bioprocesses and the creation of a patent portfolio,
in immunotherapy.

Claudine has developed 4 drug candidates and owns a wide entrepreneurial
experience after co-founding iDD biotech in 2008 and holding positions such as
Site Manager, R&D Director and member of the Management Board Committee.

Claudine Vermot-Desroches currently heads THERAWINGS Consulting - a consulting
company in therapeutic innovation, of which she is the founder.

Ghislaine Pinochet

Ghislaine Pinochet is an agricultural engineer specialized in plant protection.
She has a long experience of 38 years in multinational groups (Roussel-Uclaf,
Hoechst, Agrevo, Aventis, Bayer, BASF) where she has successively held various
positions in Development, Business and Marketing, in France and in Europe in
the field of Plant Protection and Seeds.

Since 2010, she has held various positions to establish Bayer's Seeds business
in France and in Europe and has been, more particularly, in charge of the
strategy for innovative projects.

Elaia Partners

Headquartered in Paris, Elaia is an independent private equity firm with more
than EUR350m under management and invests in seed and Series A in European
digital and deep tech start-ups (including life sciences). Elaia has
accompanied many technological successes such as Criteo (IPO), Orchestra
Networks (sold to Tibco), Sigfox, Teads (sold to Altice), Mirakl, tinyclues,
Shift Technology, etc.

About AMOEBA:

Amoéba's ambition is to become a major player in the treatment of bacterial
risk in the fields of water, healthcare and plant protection. Our biological
solution is an alternative to chemical products widely used today. Amoéba is
currently focusing on the market of industrial cooling towers estimated at
EUR1.7Bn (1) on a global chemical biocide market for water treatment, evaluated
at EUR21Bn (2) and on the biocontrol market for plant protection estimated
globally at EUR1.6Bn (4). In the future, the Company is looking at developing
new applications such as chronic wound care, estimated at EUR 751 million (3)
in the USA. Sales of associated products with healthcare, biocides and crop
protection are subject to the Company being granted local regulatory market
authorizations. The Company is currently in a trial phase for biocidal and
plant protection applications and does not market any products.

Created in 2010, based in Chassieu (Lyon, France) with a subsidiary in Canada
and in the United States, Amoéba is quoted on the compartment C of Euronext
Paris. The Company is a member of the BPIfrance Excellence network and is
eligible for the PEA-PME SME equity savings plan setup. More information on
www.amoeba-biocide.com.

(1) : Amoéba data combined from sources: DRIRE 2013, Eurostat, ARHIA 2013
(2) : Sources combined by Amoéba from water treaters, Freedonia, Eurostat et
MarketsandMarkets
(3): BCC Research, "Markets for Advanced Wound Management Technologies",
Wellesley, MA, 2017
(4): Biopesticides Worldwide Market 2013, CPL, Wallingford, UK

Contacts:

Amoéba
Valérie FILIATRE
Directeur Général Adjoint
04 26 69 16 00
valerie.filiatre@amoeba-biocide.com

Relations investisseurs
Grégory BOSSON
Agence Calyptus
01 53 65 37 90
gregory.bosson@calyptus.net

Relations médias
Constance LOZET
Agence Ekno
07 78 41 19 70
constance.lozet@ekno.fr

Disclaimer

This press release contains certain forward-looking statements concerning
AMOEBA which are based on its own assumptions and hypothesis and on information
that are available to us. However, AMOEBA gives no assurance that the estimates
contained in such forward-looking statements will be verified, which estimates
are subject to numerous risks including the risks set forth in the reference
document of AMOEBA filed with the French Financial Markets Authority (Autorité
des Marchés Financiers) on April 27, 2018 (a copy of which is available on
www.amoeba-biocide.com). The forward-looking statements contained in this press
release are also subject to risks not yet known to AMOEBA or not currently
considered material by AMOEBA. The occurrence of all or part of such risks
could cause actual results, financial conditions, performance or achievements
of AMOEBA to be materially different from such forward-looking statements.

AMOEBA's latest news

28/03/2024 18:30

AMOEBA (EPA:ALMIB) - AMOEBA: Changes in the composition of Board of Directors

Transparency directive : regulatory news

AMOEBA's latest news

Other stories